抗血小板治疗对COVID-19危重症患者生存及无器官支持天数的影响:一项随机临床试验
REMAP-CAP平台试验纳入1557例COVID-19危重症成人患者,随机接受阿司匹林(n=565)、P2Y12抑制剂(n=455)或不使用抗血小板治疗(对照,n=529),干预持续住院期间最多14天,并在抗凝血栓预防基础上进行。主要终点为21天内无器官支持天数,抗血小板组与对照组中位数均为7天(中位调整OR 1.02,95%可信区间0.86-1.23;95.7%后验概率为无效)。抗血小板组出院存活率71.5%(723/1011) vs 对照组67.9%(354/521)(中位调整OR 1.27,95%可信区间0.99-1.62;调整绝对差5%,95%可信区间-0.2%至9.5%;97%后验概率为有效)。大出血发生率抗血小板组2.1% vs 对照组0.4%(调整OR 2.97,95%可信区间1.23-8.28;调整绝对风险增加0.8%,95%可信区间0.1%-2.7%;99.4%后验概率为有害)。
要点
- 抗血小板治疗未改善21天内无器官支持天数:抗血小板组与对照组中位数均为7天(IQR -1至16),中位调整OR 1.02(95%可信区间0.86-1.23),95.7%后验概率为无效。
- 出院存活率:抗血小板组71.5%(723/1011) vs 对照组67.9%(354/521),中位调整OR 1.27(95%可信区间0.99-1.62),调整绝对差5%(95%可信区间-0.2%至9.5%),97%后验概率为有效。
- 大出血至14天:抗血小板组2.1% vs 对照组0.4%,调整OR 2.97(95%可信区间1.23-8.28),调整绝对风险增加0.8%(95%可信区间0.1%-2.7%),99.4%后验概率为有害。
- 阿司匹林与P2Y12抑制剂在自适应分析中达到预设等效标准,被统计合并后进行进一步分析。
- 合并抗血小板组与对照组比较达到预设无效标准后停止入组。
适用人群与场景
- COVID-19危重症成人患者,来自8个国家105个中心,2020年10月30日至2021年6月23日入组。
- 随机分组:阿司匹林组n=565,P2Y12抑制剂组n=455,对照组n=529;8例撤回知情同意,1549例完成试验(中位年龄57岁;521例[33.6%]女性)。
诊断标准与关键阈值
- 主要终点无器官支持天数定义为21天内存活且无需ICU呼吸或心血管器官支持的天数,范围从-1(住院期间任何死亡,删失于90天)到22(存活且无器官支持)。
- 疗效定义为OR大于1的后验概率大于99%;无效定义为与对照相比OR小于1.2的后验概率大于95%;等效定义为两个非对照干预之间OR在1/1.2至1.2之间的概率大于90%。
处置流程与药物剂量
- 干预为开放标签阿司匹林或P2Y12抑制剂,住院期间持续最多14天,并在抗凝血栓预防基础上进行。
- 入组在合并抗血小板组与对照组比较达到预设无效标准后停止。
红旗征与不能漏的情况
- 大出血至14天:抗血小板组2.1% vs 对照组0.4%,调整OR 2.97(95%可信区间1.23-8.28),99.4%后验概率为有害。
研究设计与关键结果
- 研究设计:REMAP-CAP ongoing adaptive platform trial,多干预多治疗域,随机开放标签,1557例COVID-19危重症成人,来自8个国家105个中心,随访90天(最终随访日期2021年7月26日)。
- 主要终点:21天内无器官支持天数中位数抗血小板组7(IQR -1至16) vs 对照组7(IQR -1至16),中位调整OR 1.02(95%可信区间0.86-1.23),95.7%后验概率为无效。
- 次要终点出院存活率:抗血小板组71.5%(723/1011) vs 对照组67.9%(354/521),中位调整OR 1.27(95%可信区间0.99-1.62),调整绝对差5%(95%可信区间-0.2%至9.5%),97%后验概率为有效。
- 存活者中无器官支持天数中位数两组均为14天。
- 大出血至14天:抗血小板组2.1% vs 对照组0.4%,调整OR 2.97(95%可信区间1.23-8.28),调整绝对风险增加0.8%(95%可信区间0.1%-2.7%),99.4%后验概率为有害。
证据类型、等级与局限
- 证据类型:随机临床试验(REMAP-CAP平台试验)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在COVID-19危重症成人中,与不使用抗血小板药物相比,抗血小板治疗在21天内改善无器官支持天数的可能性低。
- 抗血小板治疗组大出血风险较高(2.1% vs 0.4%),99.4%后验概率为有害。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The efficacy of antiplatelet therapy in critically ill patients with COVID-19 is uncertain.
OBJECTIVE: To determine whether antiplatelet therapy improves outcomes for critically ill adults with COVID-19.
DESIGN, SETTING, AND PARTICIPANTS: In an ongoing adaptive platform trial (REMAP-CAP) testing multiple interventions within multiple therapeutic domains, 1557 critically ill adult patients with COVID-19 were enrolled between October 30, 2020, and June 23, 2021, from 105 sites in 8 countries and followed up for 90 days (final follow-up date: July 26, 2021).
INTERVENTIONS: Patients were randomized to receive either open-label aspirin (n = 565), a P2Y12 inhibitor (n = 455), or no antiplatelet therapy (control; n = 529). Interventions were continued in the hospital for a maximum of 14 days and were in addition to anticoagulation thromboprophylaxis.
MAIN OUTCOMES AND MEASURES: The primary end point was organ support-free days (days alive and free of intensive care unit-based respiratory or cardiovascular organ support) within 21 days, ranging from -1 for any death in hospital (censored at 90 days) to 22 for survivors with no organ support. There were 13 secondary outcomes, including survival to discharge and major bleeding to 14 days. The primary analysis was a bayesian cumulative logistic model. An odds ratio (OR) greater than 1 represented improved survival, more organ support-free days, or both. Efficacy was defined as greater than 99% posterior probability of an OR greater than 1. Futility was defined as greater than 95% posterior probability of an OR less than 1.2 vs control. Intervention equivalence was defined as greater than 90% probability that the OR (compared with each other) was between 1/1.2 and 1.2 for 2 noncontrol interventions.
RESULTS: The aspirin and P2Y12 inhibitor groups met the predefined criteria for equivalence at an adaptive analysis and were statistically pooled for further analysis. Enrollment was discontinued after the prespecified criterion for futility was met for the pooled antiplatelet group compared with control. Among the 1557 critically ill patients randomized, 8 patients withdrew consent and 1549 completed the trial (median age, 57 years; 521 [33.6%] female). The median for organ support-free days was 7 (IQR, -1 to 16) in both the antiplatelet and control groups (median-adjusted OR, 1.02 [95% credible interval {CrI}, 0.86-1.23]; 95.7% posterior probability of futility). The proportions of patients surviving to hospital discharge were 71.5% (723/1011) and 67.9% (354/521) in the antiplatelet and control groups, respectively (median-adjusted OR, 1.27 [95% CrI, 0.99-1.62]; adjusted absolute difference, 5% [95% CrI, -0.2% to 9.5%]; 97% posterior probability of efficacy). Among survivors, the median for organ support-free days was 14 in both groups. Major bleeding occurred in 2.1% and 0.4% of patients in the antiplatelet and control groups (adjusted OR, 2.97 [95% CrI, 1.23-8.28]; adjusted absolute risk increase, 0.8% [95% CrI, 0.1%-2.7%]; 99.4% probability of harm).
CONCLUSIONS AND RELEVANCE: Among critically ill patients with COVID-19, treatment with an antiplatelet agent, compared with no antiplatelet agent, had a low likelihood of providing improvement in the number of organ support-free days within 21 days.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02735707.
参考来源
- Bradbury CA, Lawler PR, Stanworth SJ, et al. Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2022. PMID: 35315874. doi:10.1001/jama.2022.2910
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。